Swiss dental company vVardis secured $35 million in funding from healthcare investment firm OrbiMed for global expansion.
VVardis develops Curodont, a gel that is formulated to address early tooth decay with a drill-free, noninvasive treatment.
Swiss dental company vVardis secured $35 million in funding from healthcare investment firm OrbiMed for global expansion.
VVardis develops Curodont, a gel that is formulated to address early tooth decay with a drill-free, noninvasive treatment.